These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2285498)

  • 1. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.
    Grimes DJ; Bowles MR; Buttsworth JA; Thomson DB; Ravenscroft PJ; Nixon PF; Whiting RF; Pond SM
    Drug Saf; 1990; 5(6):447-54. PubMed ID: 2285498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemoperfusion on charcoal and hemodialysis in acute poisoning caused by methotrexate].
    Frappaz D; Bouffet E; Cochat P; Laville M; Finaz de Vilaine J; Philip T; Biron P; Zanettini MC; Latour JF; Gueho A
    Presse Med; 1988 Jun; 17(23):1209-13. PubMed ID: 2969554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity.
    Chan WK; Hui WF
    Pediatr Nephrol; 2016 Oct; 31(10):1699-703. PubMed ID: 27335061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion.
    Relling MV; Stapleton FB; Ochs J; Jones DP; Meyer W; Wainer IW; Crom WR; McKay CP; Evans WE
    Cancer; 1988 Sep; 62(5):884-8. PubMed ID: 3261621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure.
    Nemoto T; Imai C; Kaneko U; Takachi T; Iwabuchi H; Tanaka A; Nakamura G; Ogose A; Uchiyama M
    Pediatr Hematol Oncol; 2009; 26(7):520-5. PubMed ID: 19863208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
    Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
    Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency.
    Molina R; Fabian C; Cowley B
    Am J Med; 1987 Feb; 82(2):350-2. PubMed ID: 3812535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.
    Gadgil SD; Damle SR; Advani SH; Vaidya AB
    Cancer Treat Rep; 1982 May; 66(5):1169-71. PubMed ID: 7083219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose leucovorin as sole therapy for methotrexate toxicity.
    Flombaum CD; Meyers PA
    J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methotrexate poisoning: value of exchange transfusion].
    Frappaz D; Bouffet E; Biron P; Latour JF; Kassir A; Philip T; Brunat-Mentigny M
    Pediatrie; 1987; 42(4):257-60. PubMed ID: 3478650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Severe methotrexate poisoning].
    Troché G; Sacquin P; Achkar A; Korach JM; Laaban JP; Gajdos P
    Presse Med; 1991 Nov; 20(35):1724-7. PubMed ID: 1836586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoperfusion for methotrexate removal.
    Gibson TP; Reich SD; Krumlovsky FA; Ivanovich P; Gonczy C
    Clin Pharmacol Ther; 1978 Mar; 23(3):351-5. PubMed ID: 627142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose methotrexate/leucovorin adjuvant chemotherapy of osteogenic sarcoma: biochemical effects in DNA-synthesis of bone marrow cells (author's transl)].
    Sauer H; Wilmanns W
    Blut; 1978 Jun; 36(6):357-61. PubMed ID: 306851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
    Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.
    Kiu MC; Liaw CC; Yang TS; Lai GM; Hsi SN; Lu CS
    Anticancer Drugs; 1994 Aug; 5(4):480-2. PubMed ID: 7949255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.